The Filing Desk

Alector vs LENZ Therapeutics

Alector ALEC · LENZ Therapeutics LENZ · Biotechnology

Alector reported revenue of $21 million in fiscal 2025, about the same as LENZ Therapeutics' $19 million in fiscal 2025. Alector had an operating margin of -741.3%, against -477.5% at LENZ Therapeutics. Free cash flow was −$184 million at Alector and −$70 million at LENZ Therapeutics.

Side by side

AlectorLENZ Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$21M$19M
Revenue growth−79.1%—
Revenue growth a year, last 5 years−0.1%—
Gross margin—97.8%
Operating margin−741.3%−477.5%
Net margin−679.2%−430.2%
Free cash flow−$184M−$70M
Free cash flow margin−874.7%−366.7%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count6.6%35.4%
Last close$2.30$3.34
P/E at the last close6.6×—
Insider trades, last 12 monthssold $1.0 millionbought $365,553, sold $0
Piotroski F-score1 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AlectorLENZ Therapeutics
Operating margin
Percent of revenue
AlectorLENZ Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AlectorLENZ Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Alector and LENZ Therapeutics pages.